OR WAIT 15 SECS
New York, NY
Medidata Solutions, a global provider of hosted clinical development solutions, announced that inVentiv Clinical Solutions, LLC (inVentiv Clinical), the contract research organization (CRO) division of inVentiv Health, has joined Medidata’s ASPire to Win® program for CROs and other service providers. The partnership enables inVentiv to expand its clinical technology expertise and services and specialize in the delivery of the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) solution.
inVentiv Clinical offers a set of complete clinical research services to the pharmaceutical, biotech and medical device industries. In response to the growth of its CRO business and increasing customer demand for Medidata Rave, inVentiv Clinical joined the ASPire to Win program to offer a range of Rave-related services to clinical trial sponsors. In addition to providing access to clinical data that will support improved decision-making, inVentiv Clinical also anticipates using Rave to enhance its study start-up processes as well as patient and investigator recruitment. inVentiv Clinical also intends to integrate Rave with clinical technologies from its existing suite of applications to deliver accelerated trial results for sponsors.
Medidata’s ASPire to Win program selects, trains and accredits CROs and other clinical service providers to deliver Medidata Rave clinical trial technology along with their own project and data management expertise. The program offers the choice of four enablement levels—Rave Aware, Rave Ready, Rave Accredited and Rave Accredited Plus. inVentiv Clinical is currently working towards Rave Accredited Plus, training teams in both North America and Asia.
Medidata first announced ASPire to Win in April 2005 as a partner program designed to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, ASPire to Win has grown to include 24 partners, ranging from smaller clinical consultancies to large, global CROs.